Zhongdian esculent acid B1-B17 and its pharmaceutical composition and its preparation method and application

By developing Zhongdian Enlactone B1-B17 and its pharmaceutical composition, the problems of existing hepatitis cancer treatment drug single structure and drug resistance are solved, and a new anti-hepatitis cancer drug with significant cytotoxic activity against liver cancer cells is provided.

CN116478185BActive Publication Date: 2024-11-08KUNMING INST OF BOTANY CHINESE ACAD OF SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310493268.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-05-05
Publication Date
2024-11-08
Estimated Expiration
2043-05-05

AI Technical Summary

Technical Problem

The existing hepatitis cancer treatment drugs have a single structure, prone to drug resistance, and lack effective new anti-hepatitis cancer drugs.

Method used

A series of sesquiterpene dimer compounds, Zhongdeenolide B1-B17, and its preparation method are developed, and combined with a carrier as a pharmaceutical composition to prepare anti-hepatic cancer drugs.

Benefits of technology

Zhongdian Enlactone B1-B17 has significant cytotoxic activity on liver cancer cell lines, and its IC50 value is lower than that of the existing drug Sorafinib, providing new medicinal effects and potential solutions for the treatment of liver cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116478185B_ABST
    Figure CN116478185B_ABST
Patent Text Reader

Abstract

The present invention provides 17 sesquiterpene dimer compounds shown in structural formula (I), artemzhongdianolides B1-B17 (artemzhongdianolides B1-B17,1-17), and a preparation method, a pharmaceutical composition and an application thereof, belonging to the field of pharmaceutical technology. The compound has cytotoxic activity against human liver cancer cell lines HepG2, Huh7 and SK-Hep-1, can be combined with a pharmaceutically acceptable carrier to form a pharmaceutical composition, and can be used to prepare anti-liver cancer drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field:

[0001] The present invention belongs to the field of pharmaceutical technology, and specifically relates to a compound artemzhongdianolides B1-B17 (1-17), a preparation method and application thereof, a pharmaceutical composition containing the same and application thereof. Background technology:

[0002] Hepatic carcinoma is a malignant tumor of the liver. According to the source of the cancerous liver cells, hepatic carcinoma can be divided into three categories: hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and mixed liver cancer (HCC-ICC). Among them, HCC is the most common type of liver cancer, accounting for about 90% of primary liver cancer, mostly caused by chronic liver disease and cirrhosis. According to the International Agency for Research on Cancer, there will be about 900,000 new cases of liver cancer and 830,000 deaths from liver cancer in the world in 2020. my country is seriously infected with liver diseases, with about 300 million people suffering from liver diseases, and new cases of liver cancer each year account for about half of the new cases in the world. This severe situation has seriously threatened the lives and safety of the people, and has also brought a heavy economic burden to the people. Currently, the FDA-approved first-line drugs for the treatment of liver cancer include the multikinase inhibitors sorafenib and lenvatinib, and the second-line treatment drugs include regorafenib, cabozantinib, and the recombinant IgG1 monoclonal antibody ramucirumab. Two immune checkpoint inhibitors, nivolumab and pembrolizumab, have also been approved for the treatment of HCC. However, the structural types and targets of the above drugs are relatively single, and they are prone to drug resistance. Natural products have diverse structures, multiple biological activities, and different mechanisms of action. Therefore, there is an urgent need to develop new and effective anti-liver cancer drugs.

[0003] Zhongdian Artemisia (Artemisia zhongdianensis YRLing) belongs to the genus Artemisia in the Asteraceae family. It is a perennial herb distributed in the northwest of Yunnan (Zhongdian).

[0004] So far, there is no report on artemzhongdianolides B1-B17 (artemzhongdianolides B1-B17,1-17) in the prior art, nor is there any report on a pharmaceutical composition containing it as an active ingredient, nor is there any report on the use of the pharmaceutical composition in the preparation or treatment of liver cancer drugs. Summary of the invention:

[0005] The purpose of the present invention is to provide a new class of Zhongdianolides B1-B17 (artemzhongdianolides B1-B17, 1-17) with medicinal value as shown in formula (I), and a preparation method and application thereof, a pharmaceutical composition containing Zhongdianolides B1-B17 and an application thereof. This class of compounds has obvious cytotoxic activity against liver cancer cell lines and can be used to prepare anti-liver cancer drugs.

[0006] In order to achieve the above-mentioned object of the present invention, the present invention provides the following technical solutions:

[0007] The present invention provides a series of sesquiterpene dimer compounds, artemzhongdianolides B1-B17 (artemzhongdianolides B1-B17, 1-17), having a structure shown in the following formula (I):

[0008]

[0009] The present invention provides a preparation method of the above-mentioned compound 1-17. The dried aerial part of Zhongdian mugwort is crushed, and cold-extracted with 95% ethanol twice, each time for 4 days, the ethanol extracts are combined, and the ethanol extract is recovered under reduced pressure. The extract is dispersed in water and extracted with ethyl acetate, and then concentrated to obtain an ethyl acetate extraction part, and then the ethyl acetate extraction part is subjected to silica gel column chromatography, using acetone-petroleum ether in v / v, 0:100, 5:95, 10:90, 20:80, 40:60, 50:50 and 100:0 as eluent, and gradient elution is performed to obtain seven fractions of Fr.A-Fr.G; the fraction Fr.C is subjected to silica gel column chromatography and eluted with ethyl acetate-petroleum ether in v / v, 5:95, 10:90 and 20:80 to obtain five fractions Fr.C1-Fr.C5; the fraction Fr.C5 is subjected to MCI gel CHP Compounds 3, 4, 5, 6, 7, 8, and 11 were prepared by semi-preparative HPLC and gradient elution with water-methanol at a ratio of 10:90 and 0:100. The fraction Fr.D was chromatographed on an MCI gel CHP 20P column and gradient eluted with water-methanol at a ratio of 40:60, 60:40, 80:20, and 100:0 to obtain four fractions Fr.D1-Fr.D4. Fr.D1 was chromatographed on a silica gel column and gradient eluted with acetone-chloroform at a ratio of 2:98, 10:90, and 20:80 (v / v) and then subjected to semi-preparative HPLC to obtain compounds 1, 2, 9, 10, 12, 13, 14, 15, 16, and 17.

[0010] The present invention provides the use of the above compounds 1-17 in the preparation of anti-liver cancer drugs. The present invention has no particular limitation on the method of the use, and any method known in the art can be used.

[0011] The present invention also provides a pharmaceutical composition, which comprises at least one of the above-mentioned compounds 1-17 of formula (I) and a pharmaceutically acceptable carrier. At the same time, the present invention provides a method for preparing the pharmaceutical composition, wherein the above-mentioned method for preparing the compound obtains the compound 1-17, and at least one of the compounds 1-17 is taken and a pharmaceutically acceptable carrier is added.

[0012] Furthermore, the invention also provides the use of the pharmaceutical composition in preparing anti-liver cancer drugs.

[0013] When at least one of the compounds 1-17 is used to prepare an anti-liver cancer drug, the present invention preferably uses the compound 1-17 directly or in the form of a pharmaceutical composition.

[0014] The pharmaceutical composition provided by the present invention comprises at least one of the above-mentioned compounds 1-17 and a pharmaceutically acceptable carrier. In the present invention, the pharmaceutically acceptable carrier is preferably a solid, semisolid or liquid diluent, a filler and a pharmaceutical product adjuvant. The present invention has no particular limitation on the pharmaceutically acceptable carrier, and any pharmaceutically acceptable carrier well known in the art, non-toxic and inert to humans and animals can be selected.

[0015] The present invention has no particular limitation on the method for preparing the pharmaceutical composition. At least one of compounds 1-17 can be directly mixed with a pharmaceutically acceptable carrier. The present invention has no particular limitation on the mixing process. A pharmaceutical composition can be obtained by selecting a process well known in the art.

[0016] The present invention provides the use of the pharmaceutical composition of the above technical solution in the preparation of anti-liver cancer drugs. The present invention has no special limitation on the method of the application, and any method well known in the art can be used.

[0017] In the present invention, when the pharmaceutical composition is used to prepare an anti-liver cancer drug, the content of the composition in the drug is preferably 0.1-99%; in the pharmaceutical composition, the content of at least one of the compounds 1-17 in the pharmaceutical composition is preferably 0.5-90%. The pharmaceutical composition of the present invention is preferably used in the form of a dosage per unit body weight. In the present invention, the prepared drug can preferably be administered in two forms: injection (intravenous injection, intramuscular injection) and oral administration.

[0018] Compared with the prior art, the present invention has the following advantages:

[0019] 1. The present invention provides a series of new sesquiterpene dimer compounds, artemzhongdianolides B1-B17 (1-17). The present invention found that the ethanol extract of the dried aerial part of Zhongdian Artemisia has strong cytotoxic activity against three liver cancer cell lines (HepG 2, Huh7, SK-Hep-1), and further isolated 17 sesquiterpene dimer compounds with cytotoxic activity against three liver cancer cell lines, artemzhongdianolides B1-B17 (1-17).

[0020] 2. The present invention provides a new method for preparing new compounds 1-17, which has readily available raw materials, is easy to operate, and is suitable for industrial production.

[0021] 3. The present invention provides a pharmaceutical composition with new compounds 1-17 as active ingredients, providing a new anti-liver cancer drug with better medicinal effects.

[0022] 4. Compounds 1-17 of the present invention have strong cytotoxic activity against three liver cancer cell lines (HepG2, SK-HEP-1 and Huh7). For HepG2 cells, compounds 3 and 9 have strong cytotoxic activity with IC 50 The values ​​were 9.9 and 13.1 μM, which were comparable to the positive drug sorafenib. Compounds 4, 5, 7 and 13 also showed certain cytotoxic activity. 50 The values ​​were 40.3, 29.3, 21.1 and 22.1 μM, respectively. For Huh7 cells, compounds 3, 9 and 15 had strong cytotoxic activity, and their IC 50 The values ​​were 18.6, 19.5 and 18.7 μM, respectively, which were comparable to the positive drug sorafenib. For SK-Hep-1 cells, compounds 9 and 13 had strong cytotoxic activity, and their IC 50 The values ​​were 19.5 and 17.9 μM, which were comparable to the positive drug sorafenib. The above results indicate that compounds 1-17 isolated from Zhongdian mugwort can be used as drugs to treat liver cancer-related diseases. Description of the drawings:

[0023] Figure 1 Schematic diagram of the structural formula of the compound artemzhongdianolides B1-B17,1-17 of the present invention;

[0024] Figure 2 Schematic diagram of the X-ray single crystal diffraction structure of compound 1 of the present invention;

[0025] Figure 3Schematic diagram of the X-ray single crystal diffraction structure of compound 3;

[0026] Figure 4 Schematic diagram of the X-ray single crystal diffraction structure of compound 7;

[0027] Figure 5 Schematic diagram of the X-ray single crystal diffraction structure of compound 9;

[0028] Figure 6 Schematic diagram of the X-ray single crystal diffraction structure of compound 10;

[0029] Figure 7 Schematic diagram of the X-ray single crystal diffraction structure of compound 13; Specific implementation method:

[0030] In order to better understand the essence of the present invention, the test examples and embodiments of the present invention are used to further illustrate the sesquiterpene dimer compounds of the present invention, artemzhongdianolides B1-B17 (artemzhongdianolides B1-B17,1-17) and their preparation methods, structural identification, and pharmacological effects in combination with the accompanying drawings, but the present invention is not limited to these test examples and embodiments.

[0031] The technical solutions in the present invention will be described clearly and completely below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0032] Embodiment 1:

[0033] Preparation of artemzhongdianolides B1-B17, 1-17:

[0034] 25 kg of dried aerial parts of Zhongdian mugwort were crushed, and cold-extracted twice with 95% ethanol at room temperature, each time for 4 days, each time with 200 liters, and the ethanol extracts were combined, and the organic solvent was recovered under reduced pressure to obtain a crude extract, which was dispersed in water and extracted with ethyl acetate, and then concentrated to obtain 749 g of ethyl acetate part, and then the ethyl acetate extraction part was dissolved with ethyl acetate, adsorbed on 7.5 kg of silica gel (200-300 mesh) for silica gel column chromatography, and gradient elution was performed with acetone-petroleum ether in v / v, 0:100, 5:95, 10:90, 20:80, 40:60, 50:50 and 100:0 as eluents. Seven fractions of Fr.A-Fr.G (155, 94, 117, 79, 163, 66 and 52 g) were obtained by desorption; the fraction Fr.C (117 g) was eluted by silica gel column chromatography with ethyl acetate-petroleum ether at v / v ratios of 5:95, 10:90 and 20:80 to obtain five fractions Fr.C1-Fr.C5 (10, 27, 37, 20 and 16 g); the fraction Fr.C5 was eluted by silica gel column chromatography with ethyl acetate-chloroform at v / v ratios of 2:98, 10:90 and 20:80 to obtain three fractions C5.1-C5.3; the fraction Fr.C5.2 was purified by MCIgel CHP 20P column chromatography, water-methanol 10:90 and 0:100 gradient elution to obtain fractions C5.2.1-C5.2.4, fraction Fr.C5.2.4 was subjected to silica gel column chromatography with ethyl acetate-chloroform (v / v), 2:98 and 10:90 to obtain five fractions C5.2.4.1-C5.2.4.5, fraction C5.2.4.4 was subjected to semi-preparative liquid chromatography (H2O-CH3CN, 50:50, 3.0 mL / min) to obtain chemical Compound 3 (5 mg) and compound 7 (6 mg), fraction C5.2.4.5 was purified by semi-preparative liquid phase (H2O-CH3CN, 57:43, 3.0 mL / min) to obtain compound 4 (2 mg), compound 5 (3 mg), compound 6 (8 mg) and compound 8 (2 mg), and fraction C5.2.2.5 was purified by semi-preparative liquid phase (H2O-MeOH, 51:49, 3.0 mL / min) to obtain compound 11 (5 mg).

[0035] Fraction Fr.D was chromatographed on an MCI gel CHP 20P column and eluted with water-methanol at a ratio of 40:60, 60:40, 80:20 and 100:0 to give four fractions Fr.D1-Fr.D4. Fr.D2 was chromatographed on a silica gel column and eluted with acetone-chloroform at a ratio of 2:98, 10:90 and 20:80 (v / v) to give five fractions D2.1-D2.5. Fr.D2.5 was chromatographed on a silica gel column and eluted with ethyl acetate-chloroform at a ratio of 2:98, 10:90 and 20:80 (v / v) to give five fractions D2.5.1-D2.5.5. Fraction D2.5.2 was purified by semi-preparative liquid chromatography (H2O-MeOH, 46:54, 3.0 mL / min) to give compound 10 (13 mg), compound 12 (6 mg) and compound 14 (4 mg). Fr.D3 was purified by silica gel column chromatography using acetone-chloroform (v / v) at a gradient ratio of 2:98, 10:90 and 20:80 to give five fractions D3.1-D3.5. Fr.D3.1 was purified by silica gel column chromatography using acetone-petroleum ether (v / v) at a gradient ratio of 2:98, 10:90 and 20:80 to give five fractions D3.1.1-D3.1.5. Fraction D3.1.2 was purified by gel column chromatography and semi-preparative liquid chromatography (H2O-MeCN 50:50) to give compound 1 (17 mg), compound 2 (11 mg) and compound 13 (12 mg). Fraction D3.1.4 was purified by semi-preparative liquid chromatography (H2O-MeCN 50:50) to give compound 9 (30 mg), compound 15 (12 mg), compound 16 (4 mg) and 17 (4 mg).

[0036] Structural data of compound 1-17:

[0037] NMR spectra were obtained using an Avance III 600 (Bruker, Switzerland) or AvanceIII HD 400 (Bruker, Bremerhaven, Germany) superconducting nuclear magnetic resonance spectrometer, TMS (tetramethylsilane) as internal standard. High-resolution mass spectrometry analysis was determined by Shimadzu LC-MS-IT-TOF (Shimadzu, Kyoto, Japan). Infrared spectra (IR) were determined by KBr pellet method using NICOLET iS10 infrared spectrometer (Thermo Fisher Scientific, Madison, USA). ECD spectra were determined using Chirascan instrument (Applied Photophysics, Surrey, UK). Optical rotation was determined using Autopol VI polarimeter (Rudolph Research Analytical, Hackettstown, USA). Melting point was measured using X-4B micro melting point instrument was used for determination, and the melting point instrument was purchased from Shanghai Precision Scientific Instrument Co., Ltd. Thin layer chromatography silica gel plate HSGF254 was a product of Yantai Jiangyou Silica Gel Development Co., Ltd.; column chromatography silica gel (200-300 mesh) was produced by Linyi Haixiang Chemical Co., Ltd.; column chromatography dextran gel LH-20 was purchased from GE Healthcare Bio-Sciences AB. The high performance liquid chromatograph was produced by Shimadzu Corporation, the controller model was CBM-20A, the pump model was LC-20AR, the detector model was SPD-M20A, the column oven model was AT-350, and the chromatographic column model used was Agilent-Eclipse XDB-C20 (5μm, 9.4×250mm). Chromatographically pure acetonitrile was purchased from Merida, and deionized channel water was purified by MingCheTM-D 24UV MerkMillipore system. The medium pressure liquid phase (Dr Flash-Ⅱ) was produced by Shanghai Lisui Company, and the MCI column was produced by Mitsubishi Corporation of Japan, model CHP-20P (75-150 μm). Analytical grade methanol and acetonitrile were purchased from Tianjin Damao Chemical Reagent Factory. The color developing agent was 10% H2SO4-EtOH solution.

[0038]

[0039] Artemzhongdianolide B1,1

[0040] Molecular formula: C 30 H 36 O7

[0041] Molecular weight: 508.25

[0042] Properties: Monoclinic crystal

[0043] Melting point: 198~199℃

[0044] Optical rotation: (c 0.060, methanol)

[0045] HRESIMS (+) m / z: Observed value 509.2526 [M+H] + , calculated value 509.2534 [M+H] + .

[0046] IR(KBr)ν max :3523,3436,1766,1736,1661,1445,1380,1105cm -1 .

[0047] ECD(Methanol)λ max(Δε):218(+5.8),245(–4.0)nm.

[0048] Crystal data: C 30 H 36 O7·CH3OH,M=540.63, α=90°, β=102.270(3)°, γ=90°, T=100.(2)K, crystal space group P1211, Z=4, μ(Cu Kα)=0.765mm -1 The crystal data were measured using a D8 QUEST crystal diffractometer (copper target). The total number of diffraction events was 75797, and 10594 events were observed (R int =0.0617),I>2σ(I),wR(F 2 )=0.0804(I>2σ(I)),R1=0.0338,wR(F 2 )=0.0830,F 2 =1.061. Flack parameter = 0.04 (6). The crystal parameters of compound 1 have been deposited in the Cambridge Crystal Data Center, with the accession number: CCDC 2142277. Website: https: / / www.ccdc.cam.ac.uk See the crystal structure diagram for Figure 2 .

[0049] 1 H NMR and 13 C NMR (DEPT) data are shown in Tables 1 and 4.

[0050]

[0051] Artemzhongdianolide B2,2

[0052] Molecular formula: C 30 H 36 O7

[0053] Molecular weight: 508.25

[0054] Appearance: White powder

[0055] Optical rotation: (c 0.090, methanol)

[0056] HRESIMS (+) m / z: Observed value 509.2530 [M+H] + , calculated value 509.2534 [M+H] + .

[0057] IR νmax :3434,1757,1665,1439,1379,1100cm -1 .

[0058] ECD(Methanol)λ max (Δε):220(+7.2),247(–1.5)nm.

[0059] 1 H NMR and 13 C NMR (DEPT) data are shown in Tables 1 and 4.

[0060]

[0061] Artemzhongdianolide B3,3

[0062] Molecular formula: C 31 H 38 O8

[0063] Molecular weight: 538.25

[0064] Properties: Orthorhombic crystal

[0065] Optical rotation: (c 0.10, methanol)

[0066] HRESIMS (+) m / z: Observed 537.2499 [M–H]–, Calculated 537.2494 [M–H] – .

[0067] IR(KBr)νmax:3442,1765,1713,1634,1458,1384,1267,1150cm-1.

[0068] ECD (methanol) λmax (Δε): 201 (+23.6), 231 (–12.8), 328 (–2.8) nm.

[0069] Crystal data: C 31 H 38 O8,M=538.61,orthorhombic, α=90.00°, β=90.00°, γ=90.00°, T=100(2)K, crystal space group P212121, Z=4, μ(CuKα)=0.794mm -1 The crystal data were measured using a D8 QUEST crystal diffractometer (copper target). The total number of diffraction events was 30162, and 5212 events were observed (Rint =0.0333),I>2σ(I),wR(F 2 )=0.0822(I>2σ(I)),R1=0.0309,wR(F 2 )=0.0826,F 2 =1.030. Flack parameter = 0.04 (3). The crystal parameters of compound 3 have been deposited in the Cambridge Crystal Data Center, with the accession number: CCDC 2142271. Website: https: / / www.ccdc.cam.ac.uk See the crystal structure diagram for Figure 3 .

[0070] The 1H NMR and 13C NMR (DEPT) data are shown in Tables 1 and 4.

[0071]

[0072] Artemzhongdianolide B4,4

[0073] Molecular formula: C 31 H 38 O8

[0074] Molecular weight: 538.25

[0075] Appearance: White amorphous powder

[0076] Optical rotation: (c 0.060, methanol)

[0077] HRESIMS (+) m / z: Observed value 537.2497 [M–H] – , calculated value 537.2494 [M–H] – .

[0078] IR(KBr)νmax:3439,1759,1712,1632,1457,1256,1155,1006cm-1.

[0079] ECD (methanol) λmax (Δε): 214 (+12.9), 247 (–8.8), 326 (+1.2) nm.

[0080] The 1H NMR and 13C NMR (DEPT) data are shown in Tables 1 and 4.

[0081]

[0082] Artemzhongdianolide B5,5

[0083] Molecular formula: C30 H 36 O8

[0084] Molecular weight: 524.25

[0085] Appearance: White amorphous powder

[0086] Optical rotation: (c 0.047, methanol)

[0087] HRESIMS (+) m / z: Observed value 525.2492 [M+H] + , calculated value 525.2483[M+H] + .

[0088] IRνmax:3431,1765,1712,1644,1456,1377,1261,1006cm -1 .

[0089] ECD (methanol) λmax (Δε): 206 (+9.1), 229 (–4.2), 319 (–1.8) nm.

[0090] The 1H NMR and 13C NMR (DEPT) data are shown in Tables 1 and 4.

[0091]

[0092] Artemzhongdianolide B6,6

[0093] Molecular formula: C 30 H 36 O8

[0094] Molecular weight: 524.25

[0095] Appearance: White amorphous powder

[0096] Optical rotation: (c 0.078, methanol)

[0097] HRESIMS (+) m / z: Observed value 523.2351 [M–H] – , calculated value 523.2337 [M–H] – .

[0098] IRνmax:3436,1764,1711,1649,1455,1376,1255,1155cm -1 .

[0099] ECD (methanol) λmax (Δε): 202 (+16.4), 230 (–5.3), 319 (–2.8) nm.

[0100] The 1H NMR and 13C NMR (DEPT) data are shown in Tables 1 and 4.

[0101]

[0102] Artemzhongdianolide B7,7

[0103] Molecular formula: C 31 H 40 O9

[0104] Molecular weight: 556.27

[0105] Properties: Orthorhombic crystal

[0106] Optical rotation: [α] –45.0 (c 0.055, methanol)

[0107] HRESIMS (+) m / z: Observed value 601.2640 [M+HCOO] – , calculated value 601.22654 [M+HCOO] – .

[0108] IR(KBr)νmax:3443,1765,1717,1638,1457,1384,1255,969,947cm -1 .

[0109] ECD (methanol) λmax (Δε) 201 (+16.6), 231 (–2.6) nm.

[0110] Crystal data: C 31 H 40 O9,M=556.63,orthorhombic, α=90°, β=90°, γ=90°, T=100.(2)K, crystal space group P212121, Z=4, μ(Cu Kα)=0.826mm -1 The crystal data were measured using a D8 QUEST crystal diffractometer (copper target). The total number of diffraction events was 28337, and 5290 events were observed (R int =0.0414),I>2σ(I),wR(F 2 )=0.1129(I>2σ(I)),R1=0.0428,wR(F 2 )=0.1144,F2 =1.050. Flack parameter = 0.10 (5). The crystal parameters of compound 7 have been deposited in the Cambridge Crystal Data Center, with the accession number: CCDC 2142269. Website: https: / / www.ccdc.cam.ac.uk See the crystal structure diagram for Figure 4 .

[0111] The 1H NMR and 13C NMR (DEPT) data are shown in Tables 2 and 4.

[0112]

[0113] Artemzhongdianolide B8,8

[0114] Molecular formula: C 31 H 40 O9

[0115] Molecular weight: 556.27

[0116] Appearance: White amorphous powder

[0117] Optical rotation: (c 0.060, methanol)

[0118] HRESIMS (–) m / z: Observed value 555.2608 [M–H] – , calculated value 555.2600 [M–H] – .

[0119] IRνmax:3440,1752,1635,1456,1384,1261,1049,949,880cm -1 .

[0120] ECD (methanol) λmax (Δε): 203 (+3.1), 231 (–0.9), 284 (+0.1) nm.

[0121] The 1H NMR and 13C NMR (DEPT) data are shown in Tables 2 and 4.

[0122]

[0123] Artemzhongdianolide B9,9

[0124] Molecular formula: C 30 H 34 O7

[0125] Molecular weight: 506.24

[0126] Properties: Monoclinic crystal

[0127] Optical rotation: (c 0.050, methanol)

[0128] HRESIMS (–) m / z: Observed value 507.2365 [M+H] + , calculated value 507.2377[M+H] + .

[0129] IRνmax:3440,1776,1630,1452,1380,1232,1015cm -1 .

[0130] ECD (methanol) λmax (Δε): 208 (+9.6), 242 (–4.1), 277 (–2.1) nm.

[0131] Crystal data: C 30 H 34 O7·CH3OH,M=538.61,monoclinic, α=90°, β=97.084(5)°, γ=90°, T=100.(2)K, crystal space group P1211, Z=2, μ(Cu Kα)=0.777mm -1 The crystal data were measured using a D8 QUEST crystal diffractometer (copper target). The total number of diffraction events was 19863, and 5235 events were observed (R int =0.0827),I>2σ(I),wR(F 2 )=0.1503(I>2σ(I)),R1=0.0596,wR(F 2 )=0.1551,F 2 =1.041. Flack parameter = 0.06 (12). The crystal parameters of compound 9 have been deposited in the Cambridge Crystal Data Center, with the accession number: CCDC 2142274. Website: https: / / www.ccdc.cam.ac.uk See the crystal structure diagram for Figure 5 .

[0132] The 1H NMR and 13C NMR (DEPT) data are shown in Tables 2 and 4.

[0133]

[0134] Artemzhongdianolide B10,10

[0135] Molecular formula: C 30 H34 O9

[0136] Molecular weight: 538.23

[0137] Properties: Monoclinic crystal

[0138] Optical rotation: (c 0.080, methanol)

[0139] HRESIMS (+) m / z: Observed value 539.2272 [M+H] + , calculated value 539.2276[M+H] + .

[0140] IRνmax:3435,1773,1711,1646,1456,1378,1259,1135,1011cm -1 .

[0141] ECD (methanol) λmax (Δε): 223 (–2.0), 280 (–1.8), 321 (–1.7) nm.

[0142] Crystal data: C 30 H 34 O9·CH3OH,M=570.61,monoclinic, α=90°, β=97.293(4)°, γ=90°, T=100.(2)K, crystal space group P1211, Z=4, μ(Cu Kα)=0.863mm -1 The crystal data were measured using a D8 QUEST crystal diffractometer (copper target). The total number of diffraction events was 46551, and 10620 events were observed (R int =0.0980),I>2σ(I),wR(F 2 )=0.1713(I>2σ(I)),R1=0.0782,wR(F 2 )=0.1838,F 2 =1.041. Flack parameter = 0.20 (9). The crystal parameters of compound 10 have been deposited in the Cambridge Crystal Data Center, accession number: CCDC 2142273. Website: https: / / www.ccdc.cam.ac.uk See the crystal structure diagram for Figure 6 .

[0143] The 1H NMR and 13C NMR (DEPT) data are shown in Tables 2 and 5.

[0144]

[0145] Artemzhongdianolide B11,11

[0146] Molecular formula: C 30 H 36 O9

[0147] Molecular weight: 540.24

[0148] Appearance: White amorphous powder

[0149] Optical rotation: (c 0.060, methanol)

[0150] HRESIMS (+) m / z: Observed value 541.2417 [M+H] + , calculated value 541.2432[M+H] + .

[0151] IR(KBr)νmax:3440,1778,1633,1456,1384,1235,1164,1023cm -1 .

[0152] ECD (methanol) λmax (Δε): 205 (+3.8), 224 (+1.4), 242 (–0.6), 279 (–0.3) nm.

[0153] The 1H NMR and 13C NMR (DEPT) data are shown in Tables 2 and 5.

[0154]

[0155] Artemzhongdianolide B12,12

[0156] Molecular formula: C 30 H 36 O9

[0157] Molecular weight: 540.23

[0158] Appearance: White amorphous powder

[0159] Optical rotation: (c 0.050, methanol)

[0160] HRESIMS (+) m / z: Observed value 563.2245 [M+Na] + , calculated value 563.2252[M+Na] + .

[0161] IR(KBr)νmax:3435,1776,1649,1616,1443,1381,1236,1172cm -1 .

[0162] ECD (methanol) λmax 203 (+16.7), 224 (+1.6), 242 (–3.0), 280 (–1.6) nm.

[0163] 1 H NMR and 13 C NMR (DEPT) data are shown in Tables 2 and 5.

[0164]

[0165] Artemzhongdianolide B13,13

[0166] Molecular formula: C 30 H 36 O6

[0167] Molecular weight: 492.26

[0168] Properties: Orthorhombic crystal

[0169] Optical rotation: (c 0.060, methanol)

[0170] HRESIMS (+) m / z: Observed value 493.2566 [M+H] + , calculated value 493.2585[M+H] + .

[0171] IR(KBr)νmax:3436,1766,1630,1443,1380,1254,1114,1012cm -1 .

[0172] ECD (methanol) λmax (Δε): 219 (2.98) nm.

[0173] Crystal data: C 30 H 36 O6·3(CHCl3),M=850.69,orthorhombic, α=90°, β=90°, γ=90°, T=101.(2)K, crystal space group P212121, Z=4, μ(Cu Kα)=6.446mm -1The crystal data were measured using a D8 QUEST crystal diffractometer (copper target). The total number of diffraction events was 38346, and 7446 events were observed (R int =0.0730),I>2σ(I),wR(F 2 )=0.1202(I>2σ(I)),R1=0.0499,wR(F 2 )=0.1236,F 2 =1.031. Flack parameter = 0.073 (6). The crystal parameters of compound 13 have been deposited in the Cambridge Crystal Data Center, with the accession number: CCDC 2142275. Website: https: / / www.ccdc.cam.ac.uk See the crystal structure diagram for Figure 7 .

[0174] 1 H NMR and 13 C NMR (DEPT) data are shown in Tables 3 and 5.

[0175]

[0176] Artemzhongdianolide B14,14

[0177] Molecular formula: C 30 H 36 O8

[0178] Molecular weight: 524.23

[0179] Appearance: White amorphous powder

[0180] Optical rotation: (c 0.040, methanol)

[0181] HRESIMS (–) m / z: Observed value 523.2352 [M–H] – , calculated value 523.2337 [M–H] – .

[0182] IR(KBr)νmax:3434,1766,1711,1652,1446,1384,1257,1111cm -1 .

[0183] ECD (methanol) λmax (Δε): 237 (+16.4), 322 (–1.8) nm.

[0184] The 1H NMR and 13C NMR (DEPT) data are shown in Tables 3 and 5.

[0185]

[0186] Artemzhongdianolide B15,15

[0187] Molecular formula: C 30 H 34 O6

[0188] Molecular weight: 490.23

[0189] Appearance: White amorphous powder

[0190] Optical rotation: (c 0.046, methanol)

[0191] HRESIMS (–) m / z: Observed value 535.2344 [M+HCOO] – , calculated value 535.2337 [M+HCOO] – .

[0192] IR(KBr)νmax:3446,1771,1688,1638,1619,1456,1380,1257,1143,1009cm -1 .

[0193] ECD (methanol) λmax (Δε): 201 (–4.4), 217 (+9.8) nm.

[0194] 1 H NMR and 13 C NMR (DEPT) data are shown in Tables 3 and 5.

[0195]

[0196] Artemzhongdianolide B16,16

[0197] Molecular formula: C 30 H 34 O6

[0198] Molecular weight: 490.34

[0199] Appearance: White amorphous powder

[0200] Optical rotation: (c 0.040, methanol)

[0201] HRESIMS (+) m / z: Observed value 491.2435 [M+H] + , calculated value 491.2428[M+H] + .

[0202] IR(KBr)νmax:3438,1772,1716,1634,1448,1381,1242,1112cm -1 .

[0203] ECD (methanol) λmax (Δε): 217 (+10.7), 295 (+0.6) nm.

[0204] 1 H NMR and 13 C NMR (DEPT) data are shown in Tables 3 and 5.

[0205]

[0206] Artemzhongdianolide B17,17

[0207] Molecular formula: C 30 H 38 O8

[0208] Molecular weight: 526.25

[0209] Appearance: White amorphous powder

[0210] Optical rotation: (c 0.075, methanol)

[0211] HRESIMS (–) m / z: Observed value 571.2561 [M+HCOO] – , calculated value 571.2549 [M+HCOO] – .

[0212] IR(KBr)ν max :3434,1767,1736,1631,1449,1382,1256,1142,1008cm -1 .

[0213] ECD(Methanol)λ max (Δε):216(+8.6),250(–0.5)nm.

[0214] 1 H NMR and 13 C NMR (DEPT) data are shown in Tables 3 and 5.

[0215]

[0216]

[0217]

[0218]

[0219]

[0220] Embodiment 2:

[0221] Cytotoxic activity of compounds 1-17 against three liver cancer cell lines.

[0222] 1. Materials and Methods

[0223] 1.1 Materials

[0224] HepG2 cell line was donated by the Active Screening Center of Kunming Institute of Botany, Chinese Academy of Sciences; SK-Hep-1 and Huh7 cell lines were purchased from Shanghai Jining Biotechnology Co., Ltd.; culture medium (Dulbecco's Modified Eagle Medium, DMEM) was purchased from Thermo Fisher Scientific (Suzhou, China); serum (fetal bovine serum, FBS) was purchased from Life Technologies (NY, USA); RPMI-1640 was purchased from ThermoFisher Biochemical Products (Beijing, China).

[0225] 1.2 Instruments

[0226] Flex Station 3 multifunctional microplate reader (Bio-RAD 680, USA); analytical balance (AG135, Metler Toledo, China); constant temperature box (DHP-9082, Shanghai).

[0227] 1.3 Experimental process

[0228] 1). Take the hepatoma cells in logarithmic phase, discard the old culture medium, wash twice with PBS, and discard the PBS;

[0229] 2) Digest the cells with 0.25% trypsin. When the cell outline becomes darker and tends to become round under the microscope, quickly remove the trypsin.

[0230] 3) Use DMEM complete medium containing 10% FBS to terminate digestion and resuspend the cells. Take 10 μL of the cell suspension, count it with a cell counter, and adjust the cell concentration to 1×10 4 / mL, inoculated on a 96-well plate, 100 μL of cell suspension was added to each well, and incubated in a 37°C, 5% CO2 incubator for 24 h to allow the cells to adhere;

[0231] 4). Aspirate the culture medium and add the diluted sample to the plate, add 100 μL to each well, set up 3 replicate wells for each concentration, and continue incubating in the incubator for 48 hours;

[0232] 5). Aspirate the culture medium, add the prepared MTT solution (1 mg / mL), add 100 μL to each well, and incubate in the incubator for 4 hours;

[0233] 6). Aspirate the MTT solution, add DMSO, add 100 μL to each well, and incubate in the incubator for 10 minutes;

[0234] 7). Use an ELISA reader to measure the absorbance at 490 nm, and calculate the cell inhibition rate using the formula: inhibition rate = (negative - experimental group) / (negative - blank group) × 100%, and use the statistical software GraphPad prism 5 to calculate IC 50 , the experiment was repeated 3 times.

[0235] 2. Results

[0236] The cytotoxic activities of compounds 1-17 against three liver cancer cell lines (HepG2, SK-HEP-1 and Huh7) are shown in Table 6. For HepG2 cells, compounds 3 and 9 have strong cytotoxic activities, and their IC 50 The values ​​were 9.9 and 13.1 μM, respectively, which were comparable to the positive drug sorafenib; compounds 4-8, 13 and 15 also showed certain cytotoxic activity, and their IC 50 The values ​​were 40.3, 29.3, 50.2, 21.1, 54.7, 22.1, and 140.3 μM, respectively.

[0237] Compounds 3, 9 and 15 showed strong cytotoxic activity against Huh7 cells. 50 The values ​​were 18.6, 19.5, and 18.7 μM, respectively, which were comparable to the positive drug sorafenib.

[0238] Compounds 9 and 13 showed strong cytotoxic activity against SK-Hep-1 cells, with IC 50 The values ​​were 19.5 and 17.9 μM, respectively, which were comparable to the positive drug sorafenib.

[0239]

[0240] a The value is expressed as IC 50 ±SD

[0241] 3. Conclusion

[0242] The experimental results show that the cytotoxic activities of compounds 1-17 against three liver cancer cell lines (HepG2, SK-Hep-1 and Huh7) are shown in Table 6. For HepG2 cells, compounds 3 and 9 have strong cytotoxic activities, and their IC 50 The values ​​were 9.9 and 13.1 μM, respectively, which were comparable to the positive drug sorafenib; compounds 4-8, 13 and 15 also showed certain cytotoxic activity, and their IC 50 The values ​​were 40.3, 29.3, 50.2, 21.1, 54.7, 22.1, and 140.3 μM, respectively. For Huh7 cells, compounds 3, 9, and 15 had strong cytotoxic activity, and their IC 50 The values ​​were 18.6, 19.5, and 18.7 μM, respectively, which were comparable to the positive drug sorafenib. For SK-Hep-1 cells, compounds 9 and 13 had strong cytotoxic activity, and their IC 50 The values ​​were 19.5 and 17.9 μM, respectively, which were comparable to the positive drug sorafenib. The above results indicate that compounds 1-17 isolated from Zhongdian mugwort can be used as drugs for liver cancer-related diseases.

[0243] Preparation Example:

[0244] In the following formulation examples, conventional reagents are selected and the formulations are prepared according to conventional methods. This formulation example only reflects that at least one of the compounds 1-17 described in the present invention can be prepared into different formulations, and the specific reagents and operations are not specifically limited:

[0245] 1. Dissolve at least one of the compounds 1-17 of the present invention in DMSO, add water for injection according to conventional methods, filter, and sterilize by filling to prepare an injection solution, wherein the concentration of the injection solution is 0.5-5 mg / mL.

[0246] 2. Dissolve at least one of the compounds 1-17 of the present invention in DMSO, dissolve it in sterile water for injection, stir to dissolve it, filter it with a sterile suction funnel, filter it with sterile fine filtration, pack it into ampoules, freeze-dry it at low temperature, and seal it with sterile sealing to obtain a powder injection.

[0247] 3. Add at least one of the compounds 1-17 of the present invention to an excipient at a mass ratio of 9:1 to the excipient to prepare a powder.

[0248] 4. Add at least one of the compounds 1-17 of the present invention to the excipient at a mass ratio of 5:1, and granulate and tablet.

[0249] 5. Prepare at least one of the compounds 1-17 of the present invention into an oral liquid according to a conventional oral liquid preparation method.

[0250] 6. At least one of the compounds 1-17 of the present invention is added to an excipient at a mass ratio of 5:1 to the excipient to prepare a capsule.

[0251] 7. At least one of the compounds 1-17 of the present invention is added to an excipient at a mass ratio of 5:1 to the excipient to prepare granules.

[0252] It can be seen from the above embodiments that the present invention provides a Zhongdian Ai compound and its preparation method and application, a pharmaceutical composition and its application. The Zhongdian Ai lactone provided by the present invention mainly includes 17 compounds with novel structures, which have different degrees of cytotoxic activity against liver cancer cells, can be combined with pharmaceutically acceptable carriers to form a pharmaceutical composition, and can be used to prepare anti-liver cancer drugs.

[0253] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. The compound of the following structural formula is edian lactone B3-B9 (3-9), 2. The method for preparing the compound Zhongdian lactone B3-B9 (3-9) according to claim 1, characterized in that: The method comprises the following steps: the dried aerial part of Zhongdian mugwort is crushed, and cold-extracted with 95% ethanol twice, each time for 4 days, the ethanol extract is combined, the ethanol extract is recovered under reduced pressure, the extract is dispersed in water and extracted with ethyl acetate, and then concentrated to obtain the ethyl acetate extraction part, and then the ethyl acetate extraction part is subjected to silica gel column chromatography, acetone-petroleum ether is used as an eluent at 0:100, 5:95, 10:90, 20:80, 40:60, 50:50 and 100:0 in v / v, and seven fractions of Fr.A-Fr.G are obtained by gradient elution; the fraction Fr.C is subjected to silica gel column chromatography and ethyl acetate-petroleum ether is used as a v / v ratio at 5:95, 10:90 and 20:80 to obtain five fractions Fr.C1-Fr.C5; the fraction Fr.C5 is subjected to MCI gel CHP Compounds 3, 4, 5, 6, 7, and 8 were prepared by semi-preparative HPLC and gradient elution with water-methanol at a ratio of 10:90 and 0:

100. The fraction Fr.D was chromatographed on an MCI gel CHP 20P column and gradient eluted with water-methanol at a ratio of 40:60, 60:40, 80:20, and 100:0 to obtain four fractions Fr.D1-Fr.D4. Fr.D1 was chromatographed on a silica gel column and gradient eluted with acetone-chloroform at a ratio of 2:98, 10:90, and 20:80 (v / v) and then subjected to semi-preparative HPLC to obtain compound 9.

3. Use of the compound Zhongdian lactone B3-B9 (3-9) described in claim 1 in the preparation of anti-liver cancer drugs.

4. A pharmaceutical composition comprising at least one of the compounds of claim 1 and a pharmaceutically acceptable carrier.

5. Use of the pharmaceutical composition according to claim 4 in the preparation of anti-liver cancer drugs.

6. The method for preparing the pharmaceutical composition according to claim 4, characterized in that: The method comprises the following steps: the dried aerial part of Zhongdian mugwort is crushed, and cold-extracted with 95% ethanol twice, each time for 4 days, the ethanol extract is combined, the ethanol extract is recovered under reduced pressure, the extract is dispersed in water and extracted with ethyl acetate, and then concentrated to obtain the ethyl acetate extraction part, and then the ethyl acetate extraction part is subjected to silica gel column chromatography, acetone-petroleum ether is used as an eluent at 0:100, 5:95, 10:90, 20:80, 40:60, 50:50 and 100:0 in v / v, and seven fractions of Fr.A-Fr.G are obtained by gradient elution; the fraction Fr.C is subjected to silica gel column chromatography and ethyl acetate-petroleum ether is used as a v / v ratio at 5:95, 10:90 and 20:80 to obtain five fractions Fr.C1-Fr.C5; the fraction Fr.C5 is subjected to MCI gel CHP 20P column chromatography, gradient elution with water-methanol 10:90 and 0:100 and semi-preparative HPLC to prepare compounds 3, 4, 5, 6, 7, 8; fraction Fr.D was chromatographed on an MCI gel CHP 20P column, gradient eluted with water-methanol 40:60, 60:40, 80:20 and 100:0 to obtain 4 fractions Fr.D1-Fr.D4; Fr.D1 was chromatographed on a silica gel column with acetone-chloroform (v / v), gradient eluted at 2:98, 10:90 and 20:80, and then subjected to semi-preparative HPLC to obtain compound 9, and then at least one of the above compounds 3-9 was taken and a pharmaceutically acceptable carrier was added.